pBABEpuro-ERBB2 Citations (22)

Originally described in: Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.
Greulich H, Kaplan B, Mertins P, Chen TH, Tanaka KE, Yun CH, Zhang X, Lee SH, Cho J, Ambrogio L, Liao R, Imielinski M, Banerji S, Berger AH, Lawrence MS, Zhang J, Pho NH, Walker SR, Winckler W, Getz G, Frank D, Hahn WC, Eck MJ, Mani DR, Jaffe JD, Carr SA, Wong KK, Meyerson M Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14476-81. Epub 2012 Aug 20. PubMed Journal

---

Articles Citing pBABEpuro-ERBB2

Articles
Epidermal growth factor-stimulated Akt phosphorylation requires clathrin or ErbB2 but not receptor endocytosis. Garay C, Judge G, Lucarelli S, Bautista S, Pandey R, Singh T, Antonescu CN. Mol Biol Cell. 2015 Oct 1;26(19):3504-19. doi: 10.1091/mbc.E14-09-1412. Epub 2015 Aug 5. PubMed
Engineering Chimeric Receptors To Investigate the Size- and Rigidity-Dependent Interaction of PEGylated Nanoparticles with Cells. Huang WC, Burnouf PA, Su YC, Chen BM, Chuang KH, Lee CW, Wei PK, Cheng TL, Roffler SR. ACS Nano. 2016 Jan 26;10(1):648-62. doi: 10.1021/acsnano.5b05661. Epub 2016 Jan 13. PubMed
The Bag-1 inhibitor, Thio-2, reverses an atypical 3D morphology driven by Bag-1L overexpression in a MCF-10A model of ductal carcinoma in situ. Papadakis ES, Barker CR, Syed H, Reeves T, Schwaiger S, Stuppner H, Troppmair J, Blaydes JP, Cutress RI. Oncogenesis. 2016 Apr 4;5:e215. doi: 10.1038/oncsis.2016.10. PubMed
Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells. Ferreira RB, Wang M, Law ME, Davis BJ, Bartley AN, Higgins PJ, Kilberg MS, Santostefano KE, Terada N, Heldermon CD, Castellano RK, Law BK. Oncotarget. 2017 Apr 25;8(17):28971-28989. doi: 10.18632/oncotarget.15952. PubMed
A novel multi-target inhibitor harboring selectivity of inhibiting EGFR T790M sparing wild-type EGFR. Song X, Qi X, Wang Q, Zhu W, Li J. Am J Cancer Res. 2017 Sep 1;7(9):1884-1898. eCollection 2017. PubMed
Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells. Thaler S, Schmidt M, Robetawag S, Thiede G, Schad A, Sleeman JP. Oncotarget. 2017 Aug 14;8(42):72281-72301. doi: 10.18632/oncotarget.20261. eCollection 2017 Sep 22. PubMed
Progesterone impairs Herceptin effect on breast cancer cells. Kitowska K, Kowalska A, Mieszkowska M, Piasecka D, Skladanowski AC, Romanska HM, Sadej R. Oncol Lett. 2018 Feb;15(2):1817-1822. doi: 10.3892/ol.2017.7493. Epub 2017 Nov 27. PubMed
Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer. Shin DH, Jo JY, Han JY. Mol Cancer Ther. 2018 Sep;17(9):2024-2033. doi: 10.1158/1535-7163.MCT-17-1178. Epub 2018 Jun 29. PubMed
A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers. Wang M, Ferreira RB, Law ME, Davis BJ, Yaaghubi E, Ghilardi AF, Sharma A, Avery BA, Rodriguez E, Chiang CW, Narayan S, Heldermon CD, Castellano RK, Law BK. Oncogene. 2019 May;38(22):4264-4282. doi: 10.1038/s41388-019-0717-6. Epub 2019 Feb 4. PubMed
Cancer Immunotherapy with T Cells Carrying Bispecific Receptors That Mimic Antibodies. Ahn S, Li J, Sun C, Gao K, Hirabayashi K, Li H, Savoldo B, Liu R, Dotti G. Cancer Immunol Res. 2019 May;7(5):773-783. doi: 10.1158/2326-6066.CIR-18-0636. Epub 2019 Mar 6. PubMed
[fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification. Takegawa N, Tsurutani J, Kawakami H, Yonesaka K, Kato R, Haratani K, Hayashi H, Takeda M, Nonagase Y, Maenishi O, Nakagawa K. Int J Cancer. 2019 May 14. doi: 10.1002/ijc.32408. PubMed
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Robichaux JP, Elamin YY, Vijayan RSK, Nilsson MB, Hu L, He J, Zhang F, Pisegna M, Poteete A, Sun H, Li S, Chen T, Han H, Negrao MV, Ahnert JR, Diao L, Wang J, Le X, Meric-Bernstam F, Routbort M, Roeck B, Yang Z, Raymond VM, Lanman RB, Frampton GM, Miller VA, Schrock AB, Albacker LA, Wong KK, Cross JB, Heymach JV. Cancer Cell. 2019 Oct 14;36(4):444-457.e7. doi: 10.1016/j.ccell.2019.09.001. Epub 2019 Oct 3. PubMed
Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway. Wang M, Law ME, Davis BJ, Yaaghubi E, Ghilardi AF, Ferreira RB, Chiang CW, Guryanova OA, Kopinke D, Heldermon CD, Castellano RK, Law BK. Cell Death Discov. 2019 Dec 10;5:153. doi: 10.1038/s41420-019-0228-9. eCollection 2019. PubMed
Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+ breast cancer cells. DiScala M, Najor MS, Yung T, Morgan D, Abukhdeir AM, Cobleigh MA. PLoS One. 2020 Jun 11;15(6):e0234146. doi: 10.1371/journal.pone.0234146. eCollection 2020. PubMed
Uncovering mutation-specific morphogenic phenotypes and paracrine-mediated vessel dysfunction in a biomimetic vascularized mammary duct platform. Kutys ML, Polacheck WJ, Welch MK, Gagnon KA, Koorman T, Kim S, Li L, McClatchey AI, Chen CS. Nat Commun. 2020 Jul 6;11(1):3377. doi: 10.1038/s41467-020-17102-x. PubMed
Upregulation of HIF1-alpha via an NF-kappaB/COX2 pathway confers proliferative dominance of HER2-negative ductal carcinoma in situ cells in response to inflammatory stimuli. Piasecka D, Braun M, Mieszkowska M, Kowalczyk L, Kopczynski J, Kordek R, Sadej R, Romanska HM. Neoplasia. 2020 Nov;22(11):576-589. doi: 10.1016/j.neo.2020.09.003. Epub 2020 Sep 25. PubMed
Single chain variable fragment fused to maltose binding protein: a modular nanocarrier platform for the targeted delivery of antitumorals. Reche-Perez FJ, Plesselova S, De Los Reyes-Berbel E, Ortega-Munoz M, Lopez-Jaramillo FJ, Hernandez-Mateo F, Santoyo-Gonzalez F, Salto-Gonzalez R, Giron-Gonzalez MD. Biomater Sci. 2021 Mar 10;9(5):1728-1738. doi: 10.1039/d0bm01903h. PubMed
Fibroblast growth factor receptor facilitates recurrence of minimal residual disease following trastuzumab emtansine therapy. Akhand SS, Chen H, Purdy SC, Liu Z, Anderson JC, Willey CD, Wendt MK. NPJ Breast Cancer. 2021 Jan 21;7(1):5. doi: 10.1038/s41523-020-00213-5. PubMed
FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatment. Song X, Tang W, Peng H, Qi X, Li J. Invest New Drugs. 2021 Oct;39(5):1201-1212. doi: 10.1007/s10637-021-01061-1. Epub 2021 Apr 7. PubMed
ABL kinases regulate translation in HER2+ cells through Y-box-binding protein 1 to facilitate colonization of the brain. McKernan CM, Khatri A, Hannigan M, Child J, Chen Q, Mayro B, Snyder D, Nicchitta CV, Pendergast AM. Cell Rep. 2022 Aug 30;40(9):111268. doi: 10.1016/j.celrep.2022.111268. PubMed
GRB2 is a BECN1 interacting protein that regulates autophagy. Montero-Vergara J, Plachetta K, Kinch L, Bernhardt S, Kashyap K, Levine B, Thukral L, Vetter M, Thomssen C, Wiemann S, Pena-Llopis S, Jendrossek V, Vega-Rubin-de-Celis S. Cell Death Dis. 2024 Jan 5;15(1):14. doi: 10.1038/s41419-023-06387-7. PubMed
Her2 amplification, Rel-A, and Bach1 can influence APOBEC3A expression in breast cancer cells. Dennis M, Hurley A, Bray N, Cordero C, Ilagan J, Mertz TM, Roberts SA. PLoS Genet. 2024 May 28;20(5):e1011293. doi: 10.1371/journal.pgen.1011293. eCollection 2024 May. PubMed

If you have published an article using this material, please email us at to have your article added to this page.